Table 1 Correlation between circRanGAP1 and clinicopathological characteristics in 40 HCC patients
From: circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma
Characteristic | circRanGAP1 High | circRanGAP1 Low | p |
|---|---|---|---|
No. patients | 20 | 20 | Â |
Age, n (%) | 0.514 | ||
 < 55 | 9 (22.5%) | 6 (15%) |  |
 >= 55 | 11 (27.5%) | 14 (35%) | |
Sex, n (%) | 1.000 | ||
 Female | 5 (12.5%) | 4 (10%) |  |
 Male | 15 (37.5%) | 16 (40%) |  |
Tumor number, n (%) | 0.695 | ||
 >= 2 | 3 (7.5%) | 5 (12.5%) |  |
 1 | 17 (42.5%) | 15 (37.5%) |  |
Tumor size, n (%) | 0.048 | ||
 < 5cm | 4 (10%) | 11 (27.5%) |  |
 >= 5cm | 16 (40%) | 9 (22.5%) |  |
Pathologic stage, n (%) | 0.001 | ||
 I-II | 4 (10%) | 15 (37.5%) |  |
 III-IV | 16 (40%) | 5 (12.5%) |  |
Microvascular invasion, n (%) | 0.333 | ||
 No | 6 (15%) | 10 (25%) |  |
 Yes | 14 (35%) | 10 (25%) |  |
S grade, n (%) | 0.527 | ||
 S1-2 | 8 (20%) | 11 (27.5%) |  |
 S3-4 | 12 (30%) | 9 (22.5%) |  |
HBsAg, n (%) | 1.000 | ||
 Negative | 4 (10%) | 4 (10%) |  |
 Positive | 16 (40%) | 16 (40%) |  |
HCVAb, n (%) | 1.000 | ||
 Negative | 1 (2.5%) | 2 (5%) |  |
 Positive | 19 (47.5%) | 18 (45%) |  |
ALT, U/L, n (%) | 0.695 | ||
 <=75 | 15 (37.5%) | 17 (42.5%) |  |
 >75 | 5 (12.5%) | 3 (7.5%) |  |
AFP, ng/ml, n (%) | 0.320 | ||
 <=20 | 5 (12.5%) | 9 (22.5%) |  |
 >20 | 15 (37.5%) | 11 (27.5%) |  |